title: AIB1 predicts bladder cancer outcome and promotes bladder cancer cell proliferation through AKT and E2F1.
abstract: BACKGROUND
  We previously demonstrated that AIB1 overexpression is an independent molecular marker for shortened survival of bladder cancer (BC) patients. In this study, we characterised the role and molecular mechanisms of AIB1 in BC tumorigenicity.
  
  
  METHODS
  AIB1 expression was measured by immunohistochemistry in non-muscle-invasive BC tissue and adjacent normal bladder tissue. In addition, the tumorigenicity of AIB1 was assessed with in vitro and in vivo functional assays.
  
  
  RESULTS
  Overexpression of AIB1 was observed in tissues from 46 out of 146 patients with non-muscle-invasive BC and was an independent predictor for poor progression-free survival. Lentivirus-mediated AIB1 knockdown inhibited cell proliferation both in vitro and in vivo, whereas AIB1 overexpression promoted cell proliferation in vitro. The growth-inhibitory effect induced by AIB1 knockdown was mediated by G1 arrest, which was caused by reduced expression of key cell-cycle regulatory proteins through the AKT pathway and E2F1.
  
  
  CONCLUSIONS
  Our results suggest that AIB1 promotes BC cell proliferation through the AKT pathway and E2F1. Furthermore, AIB1 overexpression predicts tumour progression in patients with non-muscle-invasive BC.
authors.affiliation: Department of Radiotherapy, the First Affiliated Hospital, Anhui Medical University, Hefei 230022, China.
authors.forename: Z-T
authors.initials: ZT
authors.lastname: Tong
authors.forename: J-H
authors.initials: JH
authors.lastname: Wei
authors.forename: J-X
authors.initials: JX
authors.lastname: Zhang
authors.forename: C-Z
authors.initials: CZ
authors.lastname: Liang
authors.forename: B
authors.initials: B
authors.lastname: Liao
authors.forename: J
authors.initials: J
authors.lastname: Lu
authors.forename: S
authors.initials: S
authors.lastname: Fan
authors.forename: Z-H
authors.initials: ZH
authors.lastname: Chen
authors.forename: F
authors.initials: F
authors.lastname: Zhang
authors.forename: H-H
authors.initials: HH
authors.lastname: Ma
authors.forename: W-C
authors.initials: WC
authors.lastname: Qian
authors.forename: L-L
authors.initials: LL
authors.lastname: Kong
authors.forename: Y
authors.initials: Y
authors.lastname: Fang
authors.forename: W
authors.initials: W
authors.lastname: Chen
authors.forename: D
authors.initials: D
authors.lastname: Xie
authors.forename: J-H
authors.initials: JH
authors.lastname: Luo
mesh_terms: D000368:Aged; D000818:Animals; D002295:Carcinoma, Transitional Cell / Q000378:metabolism* / Q000473:pathology; D048708:Cell Growth Processes / Q000502:physiology; D045744:Cell Line, Tumor; D050687:E2F1 Transcription Factor / Q000235:genetics / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D008875:Middle Aged; D056921:Nuclear Receptor Coactivator 3 / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D011379:Prognosis; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics / Q000378:metabolism*; D034741:RNA, Small Interfering / Q000008:administration & dosage; D015398:Signal Transduction; D014162:Transfection; D014183:Transplantation, Heterologous; D001749:Urinary Bladder Neoplasms / Q000378:metabolism* / Q000473:pathology
chemical_list: D050687:E2F1 Transcription Factor; C493753:E2F1 protein, human; D034741:RNA, Small Interfering; C538866:NCOA3 protein, human; D056921:Nuclear Receptor Coactivator 3; D051057:Proto-Oncogene Proteins c-akt